Noteworthy

Nov 18, 2010
Pharmaceutical Executive
New CER tools grant payers the evidence they need to control drug costs
Nov 01, 2010
Pharmaceutical Executive
A timeline of some of the landmark legislation, court decisions, and drug scandals that helped forge the FDA
Nov 01, 2010
Pharmaceutical Executive
PCORI is independent and transparent and likely to alter methods for assesssing the value of new therapies
Nov 01, 2010
Pharmaceutical Executive
The CEO should be able to communicate the vision of a merger—strategically, financially, operationally, and with the entire organization in mind
Nov 01, 2010
Pharmaceutical Executive
There's been much talk of how US health reform will impact physicians, patients, and insurance companies. But how will it affect the often overlooked specialty drug market?
Nov 01, 2010
Pharmaceutical Executive
With all the money and momentum focused on medicines in emerging markets, it may be time to take a closer look at business opportunities in this more familiar neighbor to the East
Nov 01, 2010
Pharmaceutical Executive
Harvard professor Daniel Carpenter offers a piercing analysis of the FDA and sheds light on its biggest challenges
Oct 01, 2010
Pharmaceutical Executive
As Medicare, Medicaid, and the nation's web of private payers gain market power, how can pharma stay ahead of the cost-containment curve?
Oct 01, 2010
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Innovating in R&D may not be such a complicated task. Consumers simply want to find the product that gets a job done right every time
Oct 01, 2010
Pharmaceutical Executive
Ethical behavior can be a bridge-builder in an era where Big Pharma needs to find new partners. Is it up to the challenge?
native1_300x100
lorem ipsum